How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rtx-grt7039.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

RTX-GRT7039 — Competitive Intelligence Brief

RTX-GRT7039 (RTX-GRT7039) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2X3 receptor antagonist. Area: Pain Management.

phase 3 P2X3 receptor antagonist P2X3 Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

RTX-GRT7039 (RTX-GRT7039) — Grünenthal GmbH. RTX-GRT7039 is a selective antagonist of the P2X3 receptor that reduces pain signaling by blocking ATP-mediated nociceptive transmission.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
RTX-GRT7039 TARGET	RTX-GRT7039	Grünenthal GmbH	phase 3	P2X3 receptor antagonist	P2X3
3APS	3APS	Bellus Health Inc. - a GSK company	phase 3	P2X3 receptor antagonist	P2X3
MR308	MR308	Mundipharma Research GmbH & Co KG	phase 3	P2X3 receptor antagonist	P2X3
BLU-5937	BLU-5937	Bellus Health Inc. - a GSK company	phase 3	P2X3 receptor antagonist	P2X3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2X3 receptor antagonist class)

Bellus Health Inc. - a GSK company · 2 drugs in this class
Grünenthal GmbH · 2 drugs in this class
Mundipharma Research GmbH & Co KG · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RTX-GRT7039 — Competitive Intelligence Brief. https://druglandscape.com/ci/rtx-grt7039. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab